2022.07.22
I-Mab today announced that the first patient in China has been treated with TJ-CD4B in a Phase 1 IMCT for patients with solid tumors.
2022.07.18
I-Mab today announced that it will present the latest Phase 2 clinical data of lemzoparlimab in combination with azacitidine in patients with higher risk myelodysplastic syndrome as a proffered paper at 2022 ESMO Congress.
2022.07.06
I-Mab today announced that it will host its 2022 Research and Development Day on July 20, 2022.
2022.06.23
I-Mab today announced that it was ranked among the top companies in five different categories by leading global financial publication Institutional Investor.
2022.06.15
I-Mab today announced two assets the Company has licensed from partner MorphoSys are advancing globally through new license agreements.
2022.05.31
I-Mab announced the completion of patient enrollment in a Phase 3 clinical trial of eftansomatropin alfa, which is being investigated as a weekly treatment for PGHD in China.
2022.05.27
I-Mab today announced preliminary data of its ongoing Phase 2 clinical trial with uliledlimab and its global clinical development plan.
2022.05.19
The Company will hold a call with investors at 8 a.m. EST on May 27th.
2022.05.05
I-Mab today provided updates on its status under the Holding Foreign Companies Accountable Act.
2022.04.28
I-Mab announced today two key appointments of Mr. Richard Yeh as Chief Operating Officer and Dr. John Hayslip as Chief Medical Officer.